Document Detail


Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension.
MedLine Citation:
PMID:  21791937     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The use of phosphodiesterase 5 (PDE5) inhibitors to treat newborns with pulmonary hypertension is increasing. The effect of PDE5 inhibitors on the neonatal cerebral circulation remains unknown. The neonatal piglet model of chronic hypoxia-induced pulmonary hypertension allows the study of the effects of PDE5 inhibitors on both the pulmonary and cerebral circulations.
OBJECTIVES: To determine whether the PDE5 inhibitor, zaprinast, causes dilation in pulmonary and middle cerebral arteries (MCA) of normoxic newborn piglets and those with chronic hypoxia-induced pulmonary hypertension, and to evaluate whether zaprinast alters responses to increased pressure (autoregulatory ability) of the MCA.
METHODS: Two-day-old piglets were raised in normoxia or hypoxia for 3 or 10 days. Pulmonary arteries and MCA were isolated and pressurized, after which changes in diameter to zaprinast were measured. MCA pressure-diameter relationships were determined.
RESULTS: Dilation to zaprinast was similar in pulmonary arteries from normoxic and hypoxic piglets. Zaprinast dilated MCA from all groups but the response was diminished in MCA from piglets raised in hypoxia for 10 days. MCA pressure-diameter relationships (autoregulation) did not differ between the groups.
CONCLUSIONS: Pulmonary artery dilation to zaprinast supports the use of PDE5 inhibitors to treat pulmonary hypertension in neonates. PDE5 inhibitors function as MCA dilators but do not impair the pressure-diameter behavior of the cerebral circulation of either normoxic newborn piglets or those with chronic hypoxia-induced pulmonary hypertension. These findings suggest that cerebral autoregulation is likely to be intact with acute PDE5 inhibitor treatment in infants with pulmonary hypertension in conditions associated with chronic hypoxia.
Authors:
Candice D Fike; Mark Kaplowitz; Yongmei Zhang; Mark Dantuma; Jane A Madden
Related Documents :
21881527 - Left atrial size in hypertension and stroke.
8515567 - Valve replacement due to tricuspid valve anomalies in corrected transposition.
8893567 - Nonvalved homografts of thoracic aorta in operation for complex congenital cardiac dise...
2579457 - Aortic root enlargement with glycerol-preserved homologous dura mater patch during aort...
1965977 - Reliability of phlebography in the assessment of venous thrombosis in a clinical trial.
12116077 - Need for a cooperative study: pulmonary langerhans cell histiocytosis and its managemen...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-07-26
Journal Detail:
Title:  Neonatology     Volume:  101     ISSN:  1661-7819     ISO Abbreviation:  Neonatology     Publication Date:  2012  
Date Detail:
Created Date:  2011-12-22     Completed Date:  2012-07-19     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  101286577     Medline TA:  Neonatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  28-39     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Affiliation:
Department of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN 37232-0656, USA. Candice.fike@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*,  metabolism
Animals
Animals, Newborn
Anoxia / complications*
Chronic Disease
Disease Models, Animal
Hypertension, Pulmonary / drug therapy*,  etiology
Middle Cerebral Artery / drug effects*,  physiopathology
Phosphodiesterase Inhibitors / pharmacology*
Pulmonary Artery / drug effects*,  physiopathology
Purinones / pharmacology*
Swine
Vasodilation / drug effects
Grant Support
ID/Acronym/Agency:
R01 HL-68572/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Purinones; EC 3.1.4.17/3',5'-Cyclic-AMP Phosphodiesterases; GXT25D5DS0/zaprinast
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Indomethacin Impairs Coronary Perfusion in Infants with Hemodynamically Significant Ductus Arteriosu...
Next Document:  Risk Factors for Pulmonary Artery Hypertension in Preterm Infants with Moderate or Severe Bronchopul...